Oncology Nursing News

Are you available on January 31 to discuss metastatic breast cancer? Join us at the Targeted Oncology™ and Oncology Nursing News® Community Case Forum™ for an engaging evening of professional networking, case-based discussions, and insights into the evolving second-line treatment landscape for ER+/HER2- metastatic breast cancer. 📅 When: Friday, January 31, 2024 | 5:45 PM - 8:30 PM CT 📍 Where: The Pfister Hotel, Milwaukee, WI Moderator: Dana Tolman, MSN, APRN, FNP-C Advanced practice providers can earn $500 for their consultative insights, participation in polling, and a post-event survey. Don’t miss this opportunity to connect with colleagues and gain valuable knowledge over refreshments and small plates. 👉 Register now: https://ow.ly/7BWW50UFofc We can’t wait to see you there!

The FDA and Office for Human Research Protections has released draft guidance with recommendations on tissue biopsies in clinical trials for adults and children. Learn more at https://ow.ly/h8vJ50UFoMz

The FDA has granted priority review for sunvozertinib, an oral EGFR inhibitor, to treat patients with platinum-pretreated, locally advanced, or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations detected by an FDA-approved test. Read here: https://ow.ly/furt50UEKIO

Heading to the 2025 ASCO® Genitourinary Cancers Symposium? Join us on February 14 for Oncology Decoded Live!, an exclusive event featuring expert-led insights into advanced GU cancer treatments. Hosted by Manojkumar Bupathi, MD of Rocky Mountain Cancer Centers and Benjamin Garmezy, MD of Sarah Cannon Cancer Network. What to Expect: - Dynamic Discussions on the latest therapies for bladder cancer, prostate cancer, and RCC - Earn CME credits while engaging with leading healthcare providers from Texas Oncology, Urology Associates, P.C., Virginia Oncology Associates, Rocky Mountain Cancer Centers. Presented in partnership with PER®, this Cancer Network event marks the debut of our new oncology podcast series, Oncology Decoded, bringing fresh perspectives to the field of GU cancer therapies. 📍 Join us in person or virtually! 👉 Register now: https://ow.ly/Hgcy50UCRtC

The FDA has granted fast track designation to invikafusp alfa, a first-in-class selective dual T-cell agonist, for treating patients with unresectable, locally advanced, or metastatic colorectal cancer with high tumor mutational burden. Read more: https://ow.ly/45Vq50UCOxK

The phase 3 MARIPOSA trial revealed that Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant non-small cell lung cancer. Read here: https://ow.ly/SqK250UBYrX

Compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer who had not received prior systemic therapy, the phase 3 CheckMate-8HW trial found that first-line treatment with the immunotherapy combination nivolumab plus ipilimumab improved progression-free survival. Read more: https://ow.ly/A1JM50UBfkw

Results from the phase 2 SU2C-SARC032 trial showed that pembrolizumab, in combination with radiotherapy and surgery, improved disease-free survival compared to placebo in patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma of the extremity. Learn more at https://ow.ly/AKHP50UAoR7

At an Oncology Nursing News Case-Based Roundtable event, Beth Sandy, MSN, CRNP, FAPO, from the Abramson Cancer Center at the University of Pennsylvania shared the advanced practice provider perspective on the evolving role of targeted therapies for locally advanced or metastatic EGFR-mutated NSCLC. Read here: https://ow.ly/bLS550UzAgc

Data from the Phase 3 PACIFIC-5 study demonstrated that consolidation therapy with durvalumab significantly improved progression-free survival compared to placebo in patients with locally advanced, unresectable non–small cell lung cancer who did not experience disease progression after concurrent or sequential platinum-based chemoradiotherapy. Learn more at https://ow.ly/O0NW50UztB6